BACKGROUND AND PURPOSE: The local renin-angiotensin system (RAS) and cyclooxygenase-2 contribute to the activation of nuclear factor kappaB (NFkappaB) and C-reactive protein (CRP). We hypothesized that the combination of RAS blockers (RASb) and ASA reduces NFkappaB and CRP within atherosclerotic plaques. METHODS: Patients undergoing carotid endarterectomy were divided into groups according to treatment (RASb-acetylsalicylic acid [ASA], ASA, RASb, and control). The expression of NFkappaB, CRP, and CD40L was analyzed through Western blots in the obtained plaques. RESULTS: Plaques from patients treated with the combination of RASb and ASA showed lower expression of NFkappaB (25.4+/-9.8 densitometric units [DU]) than those of the control group (57.6+/-13.2 DU, P=0.03) as well as lower expression of CRP (20.9+/-9.6 DU) than those of the other treatment groups (ASA 86.1+/-13 DU, RASb 88.4+/-31 DU, controls 67.8+/-18.6, P=0.004). A negative expression of NFkappaB was associated with a reduced incidence of symptoms compared with a positive expression (5/33 [15.1%] versus 14/35 [40%], P=0.031). CONCLUSIONS: The combined treatment with RASb and ASA decreases the expression of inflammatory markers in atherosclerosis in humans. This study supports the role of the local RAS and cyclooxygenase-2 in the progression of atherosclerosis.
BACKGROUND AND PURPOSE: The local renin-angiotensin system (RAS) and cyclooxygenase-2 contribute to the activation of nuclear factor kappaB (NFkappaB) and C-reactive protein (CRP). We hypothesized that the combination of RAS blockers (RASb) and ASA reduces NFkappaB and CRP within atherosclerotic plaques. METHODS:Patients undergoing carotid endarterectomy were divided into groups according to treatment (RASb-acetylsalicylic acid [ASA], ASA, RASb, and control). The expression of NFkappaB, CRP, and CD40L was analyzed through Western blots in the obtained plaques. RESULTS: Plaques from patients treated with the combination of RASb and ASA showed lower expression of NFkappaB (25.4+/-9.8 densitometric units [DU]) than those of the control group (57.6+/-13.2 DU, P=0.03) as well as lower expression of CRP (20.9+/-9.6 DU) than those of the other treatment groups (ASA 86.1+/-13 DU, RASb 88.4+/-31 DU, controls 67.8+/-18.6, P=0.004). A negative expression of NFkappaB was associated with a reduced incidence of symptoms compared with a positive expression (5/33 [15.1%] versus 14/35 [40%], P=0.031). CONCLUSIONS: The combined treatment with RASb and ASA decreases the expression of inflammatory markers in atherosclerosis in humans. This study supports the role of the local RAS and cyclooxygenase-2 in the progression of atherosclerosis.
Authors: Soufian T AlMahameed; Gian M Novaro; Craig R Asher; Penny L Hougthaling; Rodrigo M Lago; Deepak L Bhatt; Amjad T AlMahameed; Eric J Topol Journal: Heart Asia Date: 2010-01-01
Authors: Dallit Mannheim; Joerg Herrmann; Daniele Versari; Mario Gössl; Fredric B Meyer; Joseph P McConnell; Lilach O Lerman; Amir Lerman Journal: Stroke Date: 2008-03-20 Impact factor: 7.914
Authors: Robert C Block; Amir Abdolahi; Brian Smith; N Meednu; Kelly Thevenet-Morrison; Xueya Cai; Huadong Cui; Shaker Mousa; J Thomas Brenna; S Georas Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2013-05-07 Impact factor: 4.006
Authors: David G Zacharias; Sung Gyun Kim; Alfonso Eirin Massat; Adi R Bachar; Yun K Oh; Joerg Herrmann; Martin Rodriguez-Porcel; Pinchas Cohen; Lilach O Lerman; Amir Lerman Journal: PLoS One Date: 2012-02-06 Impact factor: 3.240